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Polycystic ovary syndrome (PCOS) is associated with hyperinsuli-
nemia  and  insulin  resistance  which  may  lead  to  cardiovascular 
diseases. Evidence for cardiovascular events in women who were 
affected by PCOS during fertile age is limited. The pathogenesis is 
unknown;  however,  it  is  a  complex  multigenetic  disorder.  The 
present study was undertaken to evaluate the various cardiovas-
cular risk factors and their DNA repair efficiency in women with 
PCOS by investigating the biochemical, endocrinological and mo-
lecular cytogenetic alterations. These investigations were carried 
out in 116 women in the age group of 15-35 years clinically diag-
nosed  with  PCOS.  Data  were  compared  with  that  of  50  age-
matched healthy normal women. Fasting blood sugar (FBS), Lipid 
profile,  Follicle-Stimulating  Hormone  (FSH)  and  Luteinizing  Hor-
mone  (LH),  Prolactin  and  Estradiol  were  estimated  after  getting 
the  informed  consent.  Mutagen  induced  chromosome  sensitivity 
analysis was carried out in the lymphocytes of the subjects to as-
sess the DNA repair proficiency. Fasting Blood Sugar, total cho-
lesterol and LDL cholesterol were found to be elevated whereas 
HDL  cholesterol  was  found  to  be  lowered  in  the  test  subjects. 
FSH, LH and prolactin were also found to be significantly elevated 
in the test subjects. Change in the estradiol concentration in the 
test subjects was not significant. The mutagen sensitivity analysis 
revealed a significant elevation in break per cell (b/c) values indi-
cating a deficiency in the DNA repair mechanism / DNA damage in 
PCOS patients. Modification of life style by changing the dietary 
habit  and  sedentary  life  style  will  help  to  reduce  the  oxidative 
stress and may increase the ovarian function and a sensible life-
style management is recommended for reducing the risk for CVD. 
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olycystic ovary syndrome (PCOS) is a com-
mon condition estimated to affect 4-18% of 
women of reproductive age
1. PCOS is asso-
ciated with reproductive (hyperandrogenism, men-
strual  irregularity,  anovulation,  infertility  and  in-
creased  pregnancy  complications),  psychological 
(impaired quality of life and increased anxiety and 
depression),  metabolic  (increased  risk  factors  for 
impaired  glucose  tolerance  and  type  2  diabetes 
mellitus) and cardiovascular disease sequelae
2. 
PCOS is a spectrum of disorders with any combi-
nation  of  oligo/anovulation,  clinical  and/or  bio-
chemical  evidence  of  androgen  excess,  obesity, 
insulin resistance and polycystic ovaries on ultra-
sound. The pathogenesis is unknown; however, it 
is  a  complex  multigenetic  disorder  where  de-
creased  gonadotropin  release,  dysregulation  of 
steroidogenesis, hyperinsulinism and insulin resis-
tance plays a role
3.  
Recent  studies  have  shown  that  PCOS  is  asso-
ciated with hyperinsulinemia and insulin resistance 
and may lead to cardiovascular diseases. Although 
evidence for cardiovascular events in women who 
were affected by PCOS during fertile age is limited, 
available data suggest more frequent cardiovascu-
lar disease (CVD) in classic PCOS. In young wom-
en with PCOS, multiple risk factors for CVD includ-
ing metabolic syndrome (MS), type 2 diabetes mel-
litus (T2DM), dyslipidemia, abdominal obesity and 
hypertension  were  reported.  With  increased  adi-
posity in two thirds of American PCOS women, the 
degree  to  which  obesity  and  PCOS  interact  to 
promote  premature  atherosclerosis  and  increase 
cardiovascular  mortality  is  a  worldwide  concern. 
There  is  increasing  evidence  indicating  an  ele-
vated  prevalence  of  impaired  glucose  tolerance 
(IGT),  T2DM,  MS  and  CVD  in  PCOS.  CVD  and 
T2DM are leading causes of morbidity and mortali-
ty  in  the  Western  society  accounting  for  a  great 
proportion  of  health  care  costs
4.  These  diseases 
share common risk factors, including obesity, insu-
lin resistance, elevated blood glucose, lipid oxida-
tion  toxicity  and  low-grade  inflammation.  They 
coexist in a great number of patients. 
The existence of chromosomal aneuploidy in mul-
tinucleated  endothelial  cells  may  be  important  in 
atherogenesis by strongly  expressing low density 
lipoproteins  (LDL)  receptors  and  increasing  LDL 
uptake to the subendothelial intima. Chromosomal 
aberrations  can  also  occur  in  vascular  smooth 
muscle  cells  of  human  atherosclerotic  plaques, 
especially in unstable plaques. DNA strand breaks, 
altered purines and oxidized pyrimidines are also 
significantly  higher  in  leukocytes  of  patients  with 
CAD, and DNA strand breaks levels are higher in 
patients  with  acute  coronary  syndrome  as  com-
pared with patients with stable CAD
5.Various stu-
dies  demonstrated  the  presence  of  chromosomal 
damage  in  circulating  cells  of  patients  with  CAD 
using  the  Cytokinesis-block  micronuclei  (CBMN) 
assay
6-8. In these studies, an elevated frequency of 
micronuclei (MNs) was significantly correlated with 
both  the  occurrence  and  the  severity  of  CVD. 
Overall, these studies indicated that an increased 
MNs frequency is correlated to the pathogenesis of 
metabolic disorders and CVD risks.  
There is now a greater focus on the management 
of the metabolic consequences of PCOS, primarily 
through lifestyle intervention to achieve weight loss 
and increase physical activity
9. There are only few 
studies concerning the correlations between phe-
notypic expression, body composition and PCOS, 
and relationship with the processes of growth and 
sexual maturation and various environmental fac-
tors  (nutrition,  physical  activity,  stress,  and  other 
factors). No systematic studies were reported re-
garding  the  genetic  integrity,  especially  the  DNA 
damage in  PCOS  and the DNA repair  efficiency. 
Hence, the present study was undertaken to eva-
luate the various CVD risk factors and their DNA 
repair efficiency in women with PCOS by investi-
gating  the  hormonal,  biochemical  and  molecular 
cytogenetic alterations. 
Materials and Methods 
One hundred and sixteen women in the age group 
of 15-35 years with a clinical diagnosis of PCOS 
referred  from  RBM  Hospital,  Alappuzha,  Kerala 
formed the test group. Fifty  age-matched healthy 
women formed the control group. Informed consent 
were  obtained  from  all  the  subjects  and  detailed 
clinical  and  anthropometric  characteristics  were 
recorded  using  proforma.  Pregnant  and  lactating 
women  as  well  as  diabetic  patients  were  not  in-
cluded in the study. Neither the control nor the test 
subjects were on any treatment.  
Eight ml of venous blood was collected aseptically 
from  all  the  subjects  by  venipuncture  after  over-
night fasting. Five ml of blood was allowed to clot, 
serum  was  separated  immediately,  blood  sugar 
and  lipid  profile  were  estimated  using  Siemens 
dade dimension fully automated clinical chemistry 
analyzer. Luteinizing hormone (LH), Follicle stimu-
lating hormone (FSH), Prolactin (PRL) and Estra-
diol  were  measured  by  the  Chemiluminescence 
Immunoassay  (CLIA)  in  Centaur  CP  fully  auto-
mated CLIA analyzer of M/s. Siemens Health Care 
Diagnostics India Ltd. Reagents, calibrators, con-
trols and standards were procured from the same 
company. 
P 
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The remaining three ml of blood was collected in 
sodium heparinized vacuutainers for detecting mu-
tagen sensitivity analysis and set up the lympho-
cyte  cultures  using  RPMI  1640  as  the  medium 
supplemented  with  20%  fetal  bovine  serum  with 
10µg/ml  of  Phytohemagglutinin  and  incubated.  
The  cultures  were  treated  with  bleomycin  (0.03 
unit/ml) at S phase
10. At 70
th hour all the cultures 
were treated by colchicine to arrest the cell division 
at metaphase.  For mutagen sensitivity, the slides 
were stained with Geimsa and look for frank chro-
matid breaks. The frequency of chromatid breaks 
was considered as a measure of an individual DNA 
repair capacity. For chromosome sensitivity analy-
sis the mean break/cell (b/c) was calculated. The 
frequency  of  breaks  was  expressed  as  b/c  for 
comparison. Any individual expression of a mean 
b/c  value  <0.8  was  considered  as  hyposensitive, 
>0.8 was considered sensitive and >1.0 was con-
sidered  hypersensitive.  The  data  was  computed 
and analyzed using SPSS 11.3 for Windows. 
Results 
The demographic and physiological findings of all 
the subjects are given in table 1, 2 and 3. The age 
of study subjects ranged from 15 to 35 years with a 
mean  age  of  25.87±5.23  years.  The  age  of  the 
control subjects ranged from 17 to 35 years with a 
mean age of 27.68±4.80.  The birth order ranged 
from 1 to 9 and majority of the study subjects be-
longed to first birth order followed by third birth or-
der. Majority of the study subjects (n=78; 67.24%) 
belonged  to  rural  area  followed  by  urban  (n=24; 
20.68%)  and  coastal  area  (n=14;  12.06%).  One 
hundred  and  twelve  test  subjects  had  sedentary 
type of occupation and only 4 individuals have non 
sedentary type of occupation. Majority of the study 
subjects were married (n=79; 68.10%) and the rest 
(n=37;  31.89%)  were  unmarried.  The  duration  of 
married life of these subjects ranged from 1 to 11 
years with a mean duration of married life of 4.49 
years. Parental Consanguinity was reported only in 
8 out of 116 study subjects. Family history of infer-
tility or sub-fertility is reported in 8 out of 116 study 
subjects. Five out of 116 study subjects reported 
family history of cancer among first or second de-
gree  relatives.  Multiple  X-ray  exposures  during 
their early period were reported in 7 subjects. 
Table 1: Demographic and anthropometric characteristics of the study subjects and control subjects 
  Category 
Study subjects  Control subjects 
n (%)  n (%) 
Age range 
<21  21 (18.10)  6 (12.0) 
21-30  71 (61.20)  30 (60.0) 
>30  24 (20.69)  14 (28.0) 
Birth order 
1 to 3  84 (72.41)  40 (80.0) 
>3  32 (27.59)  10 (20.0) 
Residence 
Rural  78 (67.24)  29 (58.0) 
Urban  24 (20.69)  17 (34.0) 
Coastal  14 (20.06)  4 (8.0) 
Nature of occupation 
Sedentary  112 (96.55)  48 (96.0) 
Non sedentary  4 (3.44)  2 (4.0) 
Parental consanguinity 
Yes  8 (6.89)  1 (2.0) 
No  108 (93.10)  49 (98.0) 
Marital status 
Married  79 (68.10)  41 (82.0) 
Unmarried  37 (31.89)  9 (18.0) 
Duration of married life 
1 to 5  57 (49.14)  34 (82.93) 
>5  22 (18.97)  7 (17.07) 
Economic status 
High  12 (10.34)  27 (54.0) 
Medium  99 (85.34)  20 (40.0) 
Low  5 (4.31)  3 (6.0) 
BMI 
≤25  65 (56.03)  50 (100) 
>25  51 (43.96)  0 (0) 
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The  clinical  abnormalities  observed  in  the  study 
subjects  with  PCOS  include,  infertility  (n=45; 
38.79%), irregular menstruation (n=29; 25%), ob-
esity  (n=7;  6.03%),  primary  amenorrhea  (n=5; 
4.31%)  and  recurrent  abortions  (n=30;  25.86%). 
Majority of study subjects (n=63; 54.31%) attained 
menarche on or before 13 years of age, 48 sub-
jects attained menarche on or after 14 years of age 
and  the  remaining  5  subjects  did  not  attain  me-
narche so far. Out of the 116 test subjects, irregu-
lar menstruation in 72, regular menstruation in 39 
and  no  menstruation  in  five  were  reported.  Nine 
test subjects had endometriosis and consumption 
of  contraceptive  drugs  was  reported  in  12.  The 
body  mass  index  (BMI)  of  the  study  subjects 
showed  24.67±2.16  and  the  control  subjects 
showed 22.50±1.76, this difference had statistical 
significance  (t=6.289;  p=<0.001).  Fifty  one  out  of 
116 study subjects had  a BMI above 25 (obese) 
and rest showed a BMI of less than 25. 
The  results  of  biochemical  assessment  of  all  the 
test subjects are given in table 4. The FBS of study 
subjects  ranged  from  84-148  with  a  mean  of 
123.57±14.82  mg/dL  and  the  control  subjects 
showed  a  mean  FBS  of  99.98±10.67.  The          
difference  was  statically  significant  (t=10.171;  p= 
<0.001).  Normal  serum  total  cholesterol  was  re-
ported only in 44 study subjects and the remaining 
subjects were hypercholestrolimic (>200 mg/dL). 
Table  2:  Clinical  abnormalities  of  the  study  sub-
jects 
Clinical abnormalities  Age 
range  n (%) 
Infertility 
<21  4 (3.45%) 
21-30  38 (32.76%) 
>30  3 (2.59%) 
Irregular menstruation 
<21  13 (11.21%) 
21-30  16 (13.79%) 
>30  0 
Obesity 
<21  2 (1.72%) 
21-30  5 (4.31%) 
>30  0 
Primary amenorrhea 
<21  2 (1.72%) 
21-30  3 (2.59%) 
>30  0 
Recurrent abortions 
<21  0 
21-30  9 (7.76%) 
>30  21 (18.1%) 
Table 3: Physiological findings of the study subjects 
  Category  n (%) 
Family history of PCOS 
Yes  6 (5.17) 
No  110 (94.83) 
Family history of infertility/sub fertility 
Yes  8 (6.89) 
No  108 (93.10) 
Family history of cancer among first or second 
degree relatives 
Yes  5 (4.31) 
No  111 (95.69) 
Endometriosis 
Yes  9 (7.76) 
No  107 (92.24) 
Contraceptive drugs used 
Yes  12 (10.34) 
No  104 (89.66) 
H/o of X-ray exposure 
Yes  7 (6.03) 
No  109 (93.96) 
Menarche 
≤13  63 (54.31) 
>13  48 (41.38)  
Not yet attained  5 (4.31) 
Menstrual periods 
Regular  39 (33.62) 
Irregular  72 (62.06) 
No  5 (4.31) 
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Table 4: Comparison of fasting blood sugar and lipid profile in test and control subjects 
 
Category  Mean  SD  t  p 
Fasting blood sugar (mg/dL) 
Test (n= 116)  123.57  14.82 
10.171 
<0.001 
  Control (n=50)  99.98  10.67 
Total cholesterol(mg/dL) 
Test (n= 116)  210.88  37.39  1.402 
 
0.163 
  Control (n=50)  202.68  26.84 
HDL cholesterol(mg/dL) 
Test (n= 116)  36.37  7.32  -6.463 
 
<0.001 
  Control (n=50)  45.08  9.31 
LDL  cholesterol(mg/dL) 
Test (n= 116)  142.66  29.83  2.153 
 
0.033 
  Control (n=50)  131.36  33.61 
Triglyceride(mg/dL) 
Test (n=116)  140.97  71.92  -0.087 
 
0.931 
  Control (n=50)  141.92  44.18 
Table 5: Comparison of reproductive hormones in test and control subjects 
  Category  Mean  SD  t  p 
FSH  
Test (n=116)  25.83  6.60  15.745 
  
<0.001 
   Control (n=50)  9.64  4.65 
LH 
  
Test (n=116)  51.78  13.71  18.409 
  
<0.001 
   Control (n=50)  14.90  5.32 
Prolactin 
  
Test (n=116)  29.65  10.50  7.776 
  
<0.001 
   Control (n=50)  17.17  6.52 
Estradiol 
  
Test (n=116)  69.01  33.61  0.965 
  
0.033 
   Control (n=50)  63.63  31.30 
Table 6: Comparison of mean b/c value of the test and control subjects   
  Category  Mean  SD  t  p 
Mean b/c value 
  
Test (n=116)  0.8019  0.05  10.337 
  
<0.001 
   Control (n=50)  0.7166  0.05 
           
The  HDL  cholesterol  values  were  equal  or  less 
than  35  mg/dL  in  85  (73.27%)  in  the  study  sub-
jects. LDL cholesterol values were higher and trig-
lyceride  values  were  lower  in  the  majority  of  the 
study subjects. HDL and LDL cholesterol showed a 
significant  difference  between  the  study  and  the 
control subjects. 
FSH, LH and prolactin showed a statistically signif-
icant  difference  with  that  of  the  control  subjects. 
The study subjects showed a mean FSH value of 
25.83±6.60  whereas  in  the  control  subjects  the 
value  was  9.64±4.65  (t=15.745;  p=<0.001).  The 
mean LH level of the test subject was 51.78±13.71 
and  in  the  control  subject  the  mean  value 
was14.90±5.32 (t=18.409; p=<0.001).The prolactin 
level  was  29.65±10.50  and  17.17±6.52  (t=7.776; 
p=<0.001) respectively for the test and control sub-
jects.  The  corresponding  Estradiol  level  were 
69.01±33.61 and 63.63±31.30 for the test and con-
trol subjects but the difference was not significant 
(t=0.965; p=0.336) (Table 5). 
The mean break per cell (b/c) value of the study 
subjects was 0.8019 and that  of the control sub-
jects was 0.7166. This difference showed a statis-
tical  significance  (p=<0.001)  (Table  6).  This  indi-
cates that the subjects with PCOS had a defective 
DNA repair capacity / DNA damage than the con-
trol subjects. More over the mean b/c value of the 
subjects were found to be increasing with increase 
in risk factors or with the severity of the risk factors. 
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Table 7: Distribution of Odds ratio 
 
Category 
Total 
p  OR  95% CI  Test  Control 
n  %  n  %  n  % 
Menarche >13  36  31.0  2  4.0  38  22.9  <0.001  10.80  2.49-46.89 
LH (Abnormal)  102  87.9  8  16.0  110  66.3  <0.001  38.250  14.941-97.924 
Prolactin (Abnormal)  76  65.5  6  12.0  82  49.4  <0.001  13.93  5.47-35.48 
FBS (Abnormal)  92  79.3  9  18.0  101  60.8  <0.001  17.46  7.46-40.85 
LDL (Abnormal)  85  73.3  23  46.0  108  65.1  0.001  3.219  1.61-6.42 
HDL (Abnormal)  35  30.2  4  8.0  39  23.5  0.002  4.97  1.66-14.87 
b/c (Abnormal)  78  67.2  4  8.0  82  49.4  <0.001  23.605  7.914-70.405 
Table 8: Logistic regression analysis 
  B  S.E.  Wald  df  p  Exp(B) 
Menarche >13  3.835  1.464  6.862  1  0.009  46.305 
Prolactin (Abnormal)  2.593  0.784  10.948  1  0.001  13.370 
FBS(Abnormal)  2.538  0.728  12.144  1  0.000  12.658 
LDL (Abnormal)  0.999  0.716  1.945  1  0.163  2.716 
b/c value  1.702  0.823  4.278  1  0.039  5.482 
LH (Abnormal)  2.508  0.726  11.942  1  0.001  12.280 
HDL (Abnormal)  1.359  0.891  2.325  1  0.127  3.891 
Constant  -11.087  2.428  20.855  1  0.000  0.000 
             
Odds ratio for the following variables indicate that 
subjects  who  attained  menarche  >13  years,  in-
creased LH, Prolactin, FBS and LDL-C, decreased 
HDL-C  and  increased  b/c  value  had  significant 
contribution  for  PCOS  (Table  7).  Logistic  regres-
sion analysis revealed that the above parameters 
were  also  significant  risk  factors  for  developing 
PCOS (Table 8). 
Discussion 
In young women with PCOS, multiple risk factors 
for CVD, including metabolic syndrome (MS), type 
2  diabetes  mellitus  (T2DM),  dyslipidemia,  abdo-
minal obesity, and hypertension
11. Dyslipidemia is 
very common in PCOS patients
12 and may present 
with different patterns, including low levels of high-
density lipoprotein cholesterol (HDL-C), increased 
values  of  triglycerides  and  total  and  low-density 
lipoprotein cholesterol (LDL-C), as well as altered 
LDL  quality.  These  different  patterns  may  be  re-
lated to the associated effects of insulin resistance 
and hyperandrogenism that combine with environ-
mental  (diet,  physical  exercise)  and  genetic  fac-
tors
13,14. 
Differences  between  PCOS  and  control  women 
exist in several CVD risk factors, which often are 
more profound in obese PCOS women. The avail-
able  evidence  shows  that  different  lipid  patterns 
may be present in women with PCOS. In addition, 
differences between diverse ethnic and geographi-
cal backgrounds cannot be fully explained by var-
iations  in  body  weight  alone
13,14  but  are  likely  to 
depend  on  the  combination  of  genetic,  environ-
mental,  and  hormonal  factors.  In  support  of  this, 
non-obese women with PCOS also can have ele-
vated  levels  of  lipoprotein  (a)
15.  In  the  present 
study,  subjects  with  PCOS  showed  a  statistically 
significant level of increased biochemical and hor-
monal  risk  factors  and  also  showed  a  defective 
DNA repair capacity/DNA damage.  
The present study observed a defective DNA re-
pair  proficiency  among  subjects  with  PCOS  than 
the  control;  this  supports  the  hypothesis  that  the 
DNA damage may expand the prognostic power of 
established  biomarkers  for  the  detection  and  the 
progression from metabolic syndrome to T2D melli-
tus and CVD
7,16. Moreover, a better understanding 
of the association between DNA repair mechanism 
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and  cardiometabolic  disease  need  to  carefully 
consider a series of clinical and confounding fac-
tors such as the  quality  of the metabolic control, 
the type of diabetes, the duration of the disease, 
the influence of genetic polymorphisms, the drugs 
and radiation imaging treatment used for therapy. 
To gain more insights in the role of DNA repair ca-
pacity in cardiometabolic disease, need large pop-
ulation-based studies.  
However,  more  research  is  needed  to  provide  a 
greater  understanding  of  the  interaction  between 
hyperandrogenism,  insulin  resistance,  abdominal 
adiposity  in  PCOS  and  the  DNA  repair  capacity. 
Overall, there remain considerable gaps in the lite-
rature  which  require  further  research.  Insights  in 
these areas across the phenotypes will also assist 
in understanding the underlying pathophysiology of 
metabolic  features  of  this  condition.  Future  re-
search in PCOS should identify optimal risk predic-
tion tools forT2DM and CVD and optimal definition 
and utility of the metabolic syndrome for disease 
prediction. This will help clarify the optimal timing 
and  determine  best  screening  practices  for  mini-
mizing  cardiometabolic  morbidity  and  mortality. 
The present study demonstrated that women with 
PCOS  have  an  elevated  prevalence  of  hormonal 
imbalances;  obesity,  impaired  glucose  tolerance 
(IGT) and metabolic syndrome. Ultimately, classifi-
cation  of  the  metabolic  complications  for  each 
phenotype  will  provide  an  evidence  base  for 
screening  of  metabolic  risk  upon  diagnosis  of 
PCOS and may guide optimal treatment to prevent 
metabolic complications of PCOS. 
Conclusions 
In  the  present  study  dyslipidemia,  abnormal  hor-
monal level and increased genetic instability were 
observed in PCOS. Alarmingly, IGT and metabolic 
syndrome are highly prevalent among PCOS sub-
jects with age and weight gain worsening glycemic 
control. Lifestyle management is recommended for 
primary CVD prevention, targeting low-density and 
non-high-density lipoprotein cholesterol and adding 
insulin-sensitizing  and  other  drugs  if  dyslipidemia 
or other risk factors persist. Women with polycystic 
ovary  syndrome  should  modify  their  lifestyle  by 
changing their diet and exercise routine to reduce 
weight and improve ovarian function. This point is 
of particular interest in relation to evidence show-
ing that a range of healthy lifestyle factors, includ-
ing  exercise,  are  associated  significantly  with  re-
duced DNA damage. 
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